Profile data is unavailable for this security.
About the company
KeyMed Biosciences Inc is a biotechnology company principally engaged in the in-house discovery and development of innovative biological therapies in the autoimmune and oncology therapeutic areas. The Company also focused on the research and development of pharmaceutical products. The Company's main products comprise CM310, CM326, CM313 and CM383, mainly used for treating various type II immunological diseases in adults, adolescents and children, including moderate-to-severe atopic dermatitis (AD), moderate-to-severe asthma, CRSwNP, AR and potentially COP. The Company has also established a fully integrated platform covering the key functions of biopharmaceutical development. The Company mainly conducts its businesses in the domestic market and overseas markets.
- Revenue in HKD (TTM)991.17m
- Net income in HKD-292.44m
- Incorporated2018
- Employees1.47k
- LocationKeyMed Biosciences Inc18 Biotown Middle Road Building D2Chengdu Tianfu International BiotownCHENGDU 610219ChinaCHN
- Websitehttps://www.keymedbio.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lepu Biopharma Co Ltd | 796.00m | -201.37m | 7.36bn | 546.00 | -- | 8.24 | -- | 9.25 | -0.1177 | -0.1177 | 0.4653 | 0.4951 | 0.2917 | 2.35 | 18.33 | 1,598,400.00 | -8.24 | -24.70 | -14.39 | -37.71 | 88.41 | -- | -28.26 | -459.37 | 0.5915 | -5.03 | 0.5632 | -- | 63.21 | -- | -1,761.77 | -- | -29.86 | -- |
| Abbisko Cayman Ltd | 695.62m | 62.78m | 7.50bn | 220.00 | 127.77 | 3.43 | 19.40 | 10.78 | 0.0873 | 0.0873 | 1.10 | 3.25 | 0.2745 | -- | -- | 3,161,906.00 | 2.48 | -24.40 | 2.83 | -25.96 | 100.00 | 100.00 | 9.03 | -229.19 | -- | -- | 0.1363 | -- | 21.45 | -- | 95.21 | -- | -- | -- |
| Alphamab Oncology | 893.17m | 264.57m | 7.68bn | 484.00 | 30.08 | 3.61 | 22.22 | 8.60 | 0.2636 | 0.2636 | 0.8975 | 2.20 | 0.3492 | 0.8254 | 23.76 | 2,126,606.00 | 10.35 | -9.96 | 12.30 | -11.75 | 92.27 | -- | 29.62 | -103.28 | 4.75 | -- | 0.1285 | -- | 192.58 | -- | 178.99 | -- | -33.81 | -- |
| GenFleet Therapeutics (Shanghai) Inc | 219.84m | -1.05bn | 9.27bn | 94.00 | -- | -- | -- | 42.19 | -3.05 | -3.05 | 0.6366 | -8.69 | -- | -- | -- | -- | -- | -- | -- | -- | 80.86 | -- | -479.17 | -- | 0.1655 | -23.43 | -- | -- | 42.00 | -- | -33.31 | -- | -- | -- |
| Suzhou Ribo Life Science Co Ltd | 204.71m | -250.84m | 10.40bn | 404.00 | -- | -- | -- | 50.82 | -1.55 | -1.55 | 1.27 | -0.4107 | -- | -- | -- | -- | -- | -- | -- | -- | 90.90 | -- | -131.95 | -- | 0.9173 | -14.93 | 0.8949 | -- | 324,052.30 | -- | 36.93 | -- | -- | -- |
| Nanjing Leads Biolabs Co Ltd | 0.00 | -326.39m | 10.86bn | 192.00 | -- | 86.38 | -- | -- | -2.01 | -2.01 | 0.00 | 0.632 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.01 | -- | 0.7407 | -- | -100.00 | -- | 16.85 | -- | -- | -- |
| Keymed Biosciences Inc | 991.17m | -292.44m | 14.00bn | 1.47k | -- | 3.86 | -- | 14.12 | -1.11 | -1.11 | 3.76 | 12.15 | 0.2068 | 0.3382 | 15.10 | 787,894.80 | -6.10 | -40.63 | -7.27 | -44.60 | 95.19 | -- | -29.48 | -593.20 | 3.74 | -- | 0.2145 | -- | 20.91 | -- | -43.38 | -- | 28.05 | -- |
| Ascentage Pharma Group International | 443.89m | -1.32bn | 15.85bn | 605.00 | -- | 19.58 | -- | 35.71 | -4.03 | -4.03 | 1.36 | 2.17 | 0.1270 | 3.70 | 0.9505 | 782,867.50 | -37.68 | -30.84 | -60.56 | -41.94 | 90.87 | 94.02 | -296.81 | -252.93 | 1.53 | -- | 0.7174 | -- | 341.77 | 132.25 | 56.20 | -- | -21.49 | -- |
Data as of Mar 04 2026. Currency figures normalised to KeyMed Biosciences Inc's reporting currency: Hong Kong Dollar HKD
17.39%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 04 Feb 2026 | 8.40m | 2.81% |
| China Universal Asset Management Co., Ltd.as of 30 Jun 2025 | 7.91m | 2.65% |
| Norges Bank Investment Managementas of 30 Jun 2025 | 6.70m | 2.24% |
| Harvest Fund Management Co., Ltd.as of 30 Jun 2025 | 5.74m | 1.92% |
| ICBC UBS Asset Management Co. Ltd.as of 30 Jun 2025 | 4.75m | 1.59% |
| Bank of China Investment Management Co., Ltd.as of 30 Jun 2025 | 4.38m | 1.47% |
| Rosefinch Fund Management Co., Ltd.as of 30 Jun 2025 | 4.21m | 1.41% |
| GF Fund Management Co., Ltd.as of 30 Jun 2025 | 3.43m | 1.15% |
| HSBC Jintrust Fund Management Co. Ltd.as of 30 Jun 2025 | 3.29m | 1.10% |
| BlackRock Fund Advisorsas of 06 Feb 2026 | 3.13m | 1.05% |
More ▼
Data from 30 Jun 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
